0000950170-23-052057.txt : 20231004
0000950170-23-052057.hdr.sgml : 20231004
20231004204121
ACCESSION NUMBER: 0000950170-23-052057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231004
DATE AS OF CHANGE: 20231004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheng Andrew
CENTRAL INDEX KEY: 0001778307
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 231309591
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, 3RD FLOOR
STREET 2: C/O AKERO THERAPEUTICS, INC.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2023-10-02
0001744659
Akero Therapeutics, Inc.
AKRO
0001778307
Cheng Andrew
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
President and CEO
false
Common Stock
2023-10-02
4
M
false
25000
6.36
A
485998
D
Common Stock
2023-10-02
4
S
false
8868
46.0570
D
477130
D
Common Stock
2023-10-02
4
S
false
5300
46.8836
D
471830
D
Common Stock
2023-10-02
4
S
false
2662
48.5632
D
469168
D
Common Stock
2023-10-02
4
S
false
1700
49.7059
D
467468
D
Common Stock
2023-10-02
4
S
false
6470
50.5619
D
460998
D
Stock Option (Right to Buy)
6.36
2023-10-02
4
M
false
25000
0
D
2029-01-15
Common Stock
25000
40000
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.50, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.16 to $49.11, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.17 to $50.05, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $50.96, inclusive.
The options are vested and currently exercisable.
/s/ Jonathan Young, Attorney-in-Fact
2023-10-04